Mullerian Inhibiting Substance (MIS)

Specification

• Cat#: THP-0219
• Product Name: Mullerian Inhibiting Substance (MIS)
• Description: Mullerian inhibiting substance (MIS), also named anti‑Mullerian hormone (AMH), is a tissue-specific TGF-beta superfamily growth factor. Its expression is restricted to the Sertoli cells of fetal and postnatal testis, and to the granulosa cells of postnatal ovary.
• Species: Human
• Molecular Weight: 11.7 kDa (monomer)
• Source: E. coli-derived human MIS/AMH protein
• Introduction: The human MIS gene encodes a 553 amino acid residue (aa) prepropeptide containing a signal a sequence (1-24), a pro‑region (25-455), and the carboxyl-terminal bioactive protein (446-553) . MIS is synthesized and secreted as a disulfide-linked homodimeric pro‑protein. Proteolytic cleavage is required to generate the N-terminal pro‑region and the C‑terminal bioactive protein, which remain associated in a non-covalent complex. Recombinant C‑terminal MIS has been shown to be bioactive. However, the complex with the N-terminal pro‑region showed enhanced activity. The C‑terminal region contains the seven canonical cysteine residues found in TGF-beta superfamily members. These cysteine residues are involved in inter- and intra-molecular disulfide bonds, which forms the cysteine knot structure. Human and mouse MIS share 73% and 90% aa sequence identity in their pro‑region and C‑terminal region, respectively. MIS induces Mullerian duct (female reproductive tract) regression during sexual differentiation in the male embryo. Posnatally, MIS has been shown to regulate gonadal functions. MIS inhibits Leydig cell proliferation and is a regulator of the initial and cyclic recruitment of ovarian follicles. MIS has also been found to have anti‑proliferative effects on breast, ovarian and prostate tumor cells. Like other TGF-beta superfamily members, MIS signals via a heteromeric receptor complex consisting of a type I and a type II receptor serine/threonine kinase. Depending on the cell context, different type I receptors (including Act RIA/ALK2, BMP RIA/ALK3, and BMP RIB/ALK6) that are shared by other TGF-beta superfamily members, have been implicated in MIS signaling. In contrast, the type II MIS receptor (MIS RII) is unique and does not bind other TGF-beta superfamily members. Upon ligand binding, MIS RII recruits the non-ligand binding type I receptor into the complex, resulting in phosphorylation the BMP-like signaling pathway effector proteins Smad1, Smad5 and Smad 8.
• Purity: >97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Biological Activity: Measured by its ability to inhibit growth of OVCAR‑3 human ovarian carcinoma cells. Measured by its binding ability in a functional ELISA. Immobilized rhMIS at 3 µg/mL (100 µL/well) will bind rrMIS RII/Fc Chimera with a linear range of 1.6-100 ng/mL.
• Reconstitution: Reconstitute at 100 μg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin.
• Application: MIS has been shown to regulate gonadal functions. MIS inhibits Leydig cell proliferation and is a regulator of the initial and cyclic recruitment of ovarian follicles. MIS has also been found to have anti‑proliferative effects on breast, ovarian and prostate tumor cells.